H-IMMUNE: ESTABLISHING AN EMERGING ROLE IN IMMUNO-ONCOLOGY
H-Immune is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer.
Utilizing an immunotherapeutic approach, the company is exploring the development of novel, fully human antibody-based blockade therapeutics in an effort to generate new immuno-oncology treatments.
H-Immune was established in late 2016 as a spin-out of the French Atomic Energy Commission by Co-founders Luc Boblet, PhD, former Co-founder and CEO of Institute Pasteur spin-out PathoQuest, and Michel Léonetti, PhD, an immunologist and Senior Scientist at the French Atomic Energy Commission.
The company is located in central Paris in the new Santé Cluster of the Cochin Institute, a research center affiliated with INSERM, CNRS and Paris Descartes University and recognized as one of the largest research centers in France.
H-IMMUNE is working with outstanding researchers and key opinion leaders to exploit world class science and translational research with the ultimate goal of benefitting patients suffering from cancer.